File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ajog.2006.03.048
- Scopus: eid_2-s2.0-33750378763
- PMID: 16723109
- WOS: WOS:000242035700015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia
Title | Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia |
---|---|
Authors | |
Keywords | Chemotherapy Gestational trophoblastic neoplasia Methotrexate |
Issue Date | 2006 |
Publisher | Mosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajog |
Citation | American Journal Of Obstetrics And Gynecology, 2006, v. 195 n. 5, p. 1282-1286 How to Cite? |
Abstract | Objective: The objective of the study was to evaluate the effectiveness of single-dose methotrexate in women with low-risk gestational trophoblastic neoplasia. Study design: In this prospective observational cohort study, 105 women with low-risk gestational trophoblastic neoplasia were treated with an intravenous bolus of 100 mg/m2 of methotrexate followed by a 12-hour infusion of 200 mg/m2. If the human chorionic gonadotropin level fell 10-fold after 2 weeks, no further chemotherapy was given. Characteristics between the 2 groups with or without complete remission with this regimen were compared. Results: The overall complete remission rate with methotrexate was 84.8%, with 44.8% of women requiring a single dose of methotrexate alone. The pretreatment human chorionic gonadotropin level was found to be significantly higher in women who failed the single-dose methotrexate regimen (P = .001), and 10 of 11 patients with metastases required further doses. Conclusion: This regimen offers an effective option for women with low-risk gestational trophoblastic neoplasia without metastases and a low pretreatment human chorionic gonadotropin level. © 2006 Mosby, Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/87440 |
ISSN | 2021 Impact Factor: 10.693 2020 SCImago Journal Rankings: 3.497 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, KKL | en_HK |
dc.contributor.author | Huang, Y | en_HK |
dc.contributor.author | Tam, KF | en_HK |
dc.contributor.author | Tse, KY | en_HK |
dc.contributor.author | Ngan, HYS | en_HK |
dc.date.accessioned | 2010-09-06T09:29:41Z | - |
dc.date.available | 2010-09-06T09:29:41Z | - |
dc.date.issued | 2006 | en_HK |
dc.identifier.citation | American Journal Of Obstetrics And Gynecology, 2006, v. 195 n. 5, p. 1282-1286 | en_HK |
dc.identifier.issn | 0002-9378 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/87440 | - |
dc.description.abstract | Objective: The objective of the study was to evaluate the effectiveness of single-dose methotrexate in women with low-risk gestational trophoblastic neoplasia. Study design: In this prospective observational cohort study, 105 women with low-risk gestational trophoblastic neoplasia were treated with an intravenous bolus of 100 mg/m2 of methotrexate followed by a 12-hour infusion of 200 mg/m2. If the human chorionic gonadotropin level fell 10-fold after 2 weeks, no further chemotherapy was given. Characteristics between the 2 groups with or without complete remission with this regimen were compared. Results: The overall complete remission rate with methotrexate was 84.8%, with 44.8% of women requiring a single dose of methotrexate alone. The pretreatment human chorionic gonadotropin level was found to be significantly higher in women who failed the single-dose methotrexate regimen (P = .001), and 10 of 11 patients with metastases required further doses. Conclusion: This regimen offers an effective option for women with low-risk gestational trophoblastic neoplasia without metastases and a low pretreatment human chorionic gonadotropin level. © 2006 Mosby, Inc. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Mosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajog | en_HK |
dc.relation.ispartof | American Journal of Obstetrics and Gynecology | en_HK |
dc.rights | American Journal of Obstetrics and Gynecology. Copyright © Mosby, Inc. | en_HK |
dc.subject | Chemotherapy | en_HK |
dc.subject | Gestational trophoblastic neoplasia | en_HK |
dc.subject | Methotrexate | en_HK |
dc.title | Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0002-9378&volume=195 &issue=Issue 5&spage=1282&epage=1286&date=2006&atitle=Single-dose+methotrexate+regimen+in+the+treatment+of+low-risk+gestational+trophoblastic+neoplasia | en_HK |
dc.identifier.email | Chan, KKL:kklchan@hkucc.hku.hk | en_HK |
dc.identifier.email | Ngan, HYS:hysngan@hkucc.hku.hk | en_HK |
dc.identifier.authority | Chan, KKL=rp00499 | en_HK |
dc.identifier.authority | Ngan, HYS=rp00346 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ajog.2006.03.048 | en_HK |
dc.identifier.pmid | 16723109 | - |
dc.identifier.scopus | eid_2-s2.0-33750378763 | en_HK |
dc.identifier.hkuros | 147211 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33750378763&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 195 | en_HK |
dc.identifier.issue | 5 | en_HK |
dc.identifier.spage | 1282 | en_HK |
dc.identifier.epage | 1286 | en_HK |
dc.identifier.isi | WOS:000242035700015 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Chan, KKL=8655666700 | en_HK |
dc.identifier.scopusauthorid | Huang, Y=15044554300 | en_HK |
dc.identifier.scopusauthorid | Tam, KF=7201692816 | en_HK |
dc.identifier.scopusauthorid | Tse, KY=8876026900 | en_HK |
dc.identifier.scopusauthorid | Ngan, HYS=34571944100 | en_HK |
dc.identifier.issnl | 0002-9378 | - |